multi target TKI

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)renal-cell carcinoma (advanced) All type of patientHR+ HER2 -       combination with CTcombination with endocrine therapycombination with taxanesTKIVEGFR, MET AXL TKI apitolisib cabozantinib tivozanib axitinibdovitiniblapatinib paclitaxelpazopanibsorafenibsunitinib vs CT alonevs endocrine therapy alonevs taxanes alone       1st line2nd lineHER-2 negativeHER-2 positiveHR positivepreviously treated by HER-2 antibodypreviously treated by taxanes

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (17)death (overall survival) (12)Serious adverse event (3)progression (Time to progression TTP) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
advanced breast cancer (metastatic)
lapatinib
Johnston (EGF30008) , 2009      NCT	lapatinib + letrozole	letrozole alone		HR positive	Low risk of bias	conclusive
Di Leo, 2008        NCT	lapatinib + paclitaxel	paclitaxel alone		1st line	Low risk of bias	negative
sorafenib
Baselga, 2012	sorafenib + capecitabine	capecitabine alone		HER-2 negative	Low risk of bias	suggesting
Schwartzberg, 2013      NCT	sorafenib + gemcitabine or capecitabine	gemcitabine or capecitabine alone		2nd line HER-2 negative	Exploratory	suggesting
Gradishar, 2013	sorafenib + paclitaxel	paclitaxel alone		1st line HER-2 negative	Low risk of bias	negative
renal-cell carcinoma (advanced)
apitolisib
Powles, 2014	apitolisib	everolimus				-
axitinib
AXIS (Rini), 2011      NCT	axitinib	sorafenib				suggesting
Qin, 2012	axitinib	sorafenib				-
cabozantinib
METEOR, 2015    NCT	cabozantinib	everolimus	after VEGFR-targeted therapy failure	2nd line	Risk of bias	suggesting
CABOSUN, 2017      NCT	cabozantinib	sunitinib	first-line therapy in patients with intermediate- or poor-risk	1st line	Exploratory	suggesting
dovitinib
GOLD      NCT	dovitinib	sorafenib			Risk of bias	negative
pazopanib
Sternberg, 2010	pazopanib	placebo			Low risk of bias	suggesting
VEG105192, 2010        NCT	pazopanib	placebo				suggesting
COMPARZ, 2013      NCT	pazopanib	sunitinib				negative
sorafenib
Escudier, 2009	sorafenib	interferon alpha			Exploratory	negative
TARGET, 2007          NCT	sorafenib	placebo			Low risk of bias	suggesting
Ratain, 2006	sorafenib	placebo			Exploratory	-
sunitinib
Motzer, 2007          NCT	sunitinib	interferon alpha				suggesting
SWITCH      NCT	sunitinib	sorafenib				-
tivozanib
TIVO-1, 2013      NCT	tivozanib	sorafenib				suggesting